# Moderna Inc.

Type: Company (MRNA)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/moderna-inc
Canonical HTML page: https://gethealthbrief.com/entity/moderna-inc

## Timeline

- **2026-07-20**: Cramer Endorsement & 109% YTD Gain — Motley Fool highlights 109% year-to-date surge and Jim Cramer's comment that Moderna is 'finally investable again'.
- **2026-06**: Quarterly Update — Moderna reports a 26% reduction in operating expenses, reiterates up to 10% revenue growth target for 2026.
- **2026-03-15**: Public Criticism — Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem.
- **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns.
- **2025-12-31**: Grants Rescinded — The administration pulls back hundreds of millions in funding for mRNA-based research projects.
- **2024-08-15**: Trial Design Support — FDA officials reportedly signal support for Moderna's flu vaccine trial workaround and data submission plan.
- **2022**: Post-Pandemic Decline — Demand for COVID vaccines wanes, RSV sales miss expectations, and CMV candidate fails; stock loses over 80% from peak.
- **2021-08-01**: Peak Valuation — Moderna reaches a market capitalization of $200 billion during the height of pandemic vaccine distribution.
- **2020**: COVID Vaccine Success — Moderna's COVID-19 vaccine drives record revenue; stock surges over 2,000% from early 2020 through August 2021.

## Recent coverage (3 stories)

### Moderna's 109% Stock Surge: What It Means for Global Health and mRNA Vaccines
2026-07-21 00:07:56 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Moderna’s financial rebound could accelerate the deployment of mRNA technology for RSV, flu, and future pandemics, enhancing public health resilience.
Full story: https://gethealthbrief.com/story/moderna-health-mrna-impact-109

### Moderna Rockets 13% to 2024 Highs as Healthcare Outperforms
2026-06-28 00:00:21 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moderna surged nearly 13% after an investor event, driving a broader healthcare rally as investors rotated out of tech. The S&P 500 healthcare sector benefited from defensive positioning amid AI chip turmoil.
Full story: https://gethealthbrief.com/story/moderna-13-percent-healthcare-rally-june26

### FDA's Regulatory Shift Signals New Era of Uncertainty for mRNA Innovation
2026-03-16 00:16:10 · Sentiment: Negative · Impact: 8/10 · Sources: 2

The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response.
Full story: https://gethealthbrief.com/story/fda-moderna-mrna-regulatory-uncertainty

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.